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from the editor

volume 54, number 2

Yale’s Actions and Response to Coronavirus (COVID-19) website, covid.yale.edu, provides
such information as clinical and laboratory research, patient care, resources to both track
the spread of the virus and help cope during this crisis, COVID-19 news, and messages.
For many years, this section was
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dialogue

		 The road back
to New Haven
just weeks into her tenure as the 19th dean of Yale
School of Medicine, Nancy J. Brown, MD, found herself
thrust into the center of a global pandemic. She shared her
thoughts with Yale recently on the state of the school, and
its efforts to help turn the tide against COVID-19.
How have Yale School of Medicine doctors responded to the influx of
patients with COVID-19? Our response to COVID-19 has brought out the

caring, collegiality, and creativity of our people. Clinical leaders are
working hard to ensure that we have personal protective equipment,
sufficient capacity in the hospital, and enough clinicians. Clinical
Virology Laboratory developed testing for COVID-19 in-house, and this
has made rapid testing available for health care workers.
Our critical care physicians have stood up and equipped hospital
floors dedicated to the care of COVID-19 patients, with more space
on the way. To decrease the number of ambulatory patients, our faculty have greatly expanded telehealth services. Clinical leaders have
conferred with colleagues throughout the world to learn from their
experience and strengthen our response.
What research is taking place around the virus? Epidemiologists across

the health science schools have been modeling the pandemic to allow
us to focus resources where and when they are needed. Our worldclass immunologists have shifted their programs to understand how
COVID-19 infects cells, the immune system’s response, and how to
interrupt that process. Our geneticists are exploring how patient factors determine outcome. Data scientists study outcomes in patients
using electronic health records. We are sharing these methods with
other institutions to facilitate effective research, and are leveraging the infrastructure of the Yale Center for Clinical Investigation to
quickly initiate clinical studies of new therapies.

R O B E R T A . L I S A K P H OTO

Other than moving to online classes, what is the effect on medical students?

We had to interrupt the clinical clerkship training, which provides
medical students with clinical experience. Students are valuable
members of the care team, but with the decrease in ambulatory visits
and elective surgeries, clerkships didn’t make sense. Students are
working with their advisors to develop individually tailored plans.
Many have volunteered to conduct literature searches for our teams,
just as they would on the wards. The students also suggested creating an elective on COVID-19 and pandemics. This is a trying time, but
challenge can also mean opportunity.

Winter 2020
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»

			Laying the
		groundwork
in december 2019, Merck received FDA approval for
the Ebola vaccine trademarked Ervebo. Merck had distributed this vaccine for free in the Democratic Republic
of the Congo over the last year and a half. The vaccine
is based on a viral vector developed in the lab of John
Rose, PhD, professor emeritus of pathology and senior
research scientist in the Department of Pathology during
an eight-year period in the 1990s. Rose is currently the
director of Yale’s Molecular Virology Program. The Ebola
vaccine based on Rose’s research has proven to be close to
100% effective in preventing Ebola infection.
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“It’s incredibly rewarding to
know that one’s efforts have
made a tangible difference in the
world,” said Rose. “Merck has
provided the vaccine for free to
over 250,000 people.”
Rose said that the project started out as a method
to develop a general vaccine
platform for viruses and other
pathogens. His lab’s work with
this vaccine system focused
initially on multiple viruses
including HIV, a notoriously
tricky and mutable foe. His
laboratory also distributed the
viral genetic system to over 100
other labs, including the one
that eventually developed the
Ebola vaccine.
The method relies on genetic
engineering of a relatively benign
animal virus called vesicular
stomatitis virus (VSV) to express
protein antigens from dangerous
viruses or other pathogens. This
system can be used to generate
vaccines against multiple threats.
For example, it can even protect
against plague caused by the
Yersinia pestis bacterium.
It can also protect against
coronaviruses. Rose and colleagues published a paper in
2005 demonstrating a VSVbased vaccine that protects
against SARS coronavirus in the
wake of the SARS outbreak.
“A VSV vector worked for
SARS, so almost certainly will
for other coronaviruses like
the 2019-nCoV,” wrote Rose via
email. “The recombinant vaccine could be made in a week,
but approval for use could take

years. SARS was contained
through public health measures,
long before a vaccine could be
tested and approved.”
While the legal mechanisms
by which different vaccines
are tested and approved for use
are endeavors in their own right
apart from research, the news
is good: if the current outbreak
of coronavirus were to intensify
dangerously, researchers
would have little difficulty in
creating vaccines.
Vaccines for HIV and Zika
using the VSV platform are still
under development, but show
great promise. And Rose is happy
his team had an opportunity
to work on a project of lasting
importance. “The researchers
who worked on this project are
spread to the four winds, and
many have their own labs now,”
he said. “Knowing that we’ve
made a significant contribution
to humankind in terms of understanding how viruses work, and
offering ways to combat them, is
a very good feeling.”
—Adrian Bonenberger

»
S C I E N T I F I C I M AG E S P R OV I D E D B Y TO M B U R R AG E & M I C H A E L W H I T T

Researching a
clinical mystery

When Daniel Wong was overcome by seizures that struck
out of the blue only two
months after he graduated from
Stanford in 2013, his doctors
were alarmed. They could find
no triggering event, no history
of epilepsy, no explanation for
his sudden prolonged seizures.

Electron micrographs of
VSV particles, taken in
the laboratory of John
“Jack” Rose. They show
(clockwise from above)
the bullet-shaped “magic
bullets” engineered to
carry extra genes and
make vaccines, an infected animal cell where
thousands of VSV particles are budding from
the cell’s surface, and,
finally, an enlargement
of the surface showing
the budding bullets.
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Yale School of
Medicine researchers
such as Christopher H.
Gottschalk, MD, and
Deena Kuruvilla, MD,
are looking at ways to
stop migraine. They’ve
found that certain
medications work
on the inflammatory
cascade that plays a
role in producing oftentimes debilitating
pain for the patient.
For more on migraine,
visit ymm.yale.edu/
migraine
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Doctors placed the 22-year-old
Daniel in a drug-induced coma
to protect his brain and tried
numerous therapies to control
his seizures. All treatments
failed. Less than three months
later, Daniel died without
regaining consciousness.
At the suggestion of one of
his doctors, Daniel’s parents,
Nora and Raymond Wong (both
graduates of Yale College) met
with Yale School of Medicine
(YSM) neurologists Lawrence J.
Hirsch, MD ’91; Emily J. Gilmore,
MD; and Nicolas Gaspard, PhD,
at Yale New Haven Hospital in
August 2014. The clinicians were
planning a multinational, multicenter study to include patients
like Daniel—who was thought to
have a syndrome referred to as
new-onset refractory status epilepticus or NORSE.
NORSE is described as a
clinical presentation of prolonged seizures that are
uncontrolled by at least two
antiseizure medications, with
the cause of the seizures
remaining unidentifiable
for 72 hours. NORSE tends to
affect primarily healthy young
adults and children with no
previous history of epilepsy.
The consequences of the disorder are devastating. There
is significant short-term
mortality (as high as 27%)
and morbidity. Patients often
survive with significant brain
damage and develop chronic
epilepsy. The Wongs created
the Daniel Raymond Wong
Neurology Research Fund at

YSM to support this prospective observational study that
collects clinical data from
NORSE patients and their biospecimens, both of which are
banked at Yale.
With Hirsch and Gaspard
as co-chairs of her medical
advisory board, Nora Wong
established the NORSE Institute
(norseinstitute.org), a collaboration of NORSE families, clinicians, and basic scientists. In
the past five years, the NORSE
Institute has worked to raise
awareness of this rare disorder.
At Nora’s request, Hirsch and
Gaspard wrote the first description of NORSE issued on the rare
disease websites hosted by the
National Institutes of Health’s
Genetic and Rare Diseases

Information Center (GARD),
the National Organization for
Rare Disorders (NORD), and the
Epilepsy Foundation.
To build a common language for the disorder, Hirsch
assembled a group of international experts to develop consensus definitions of NORSE
and a related syndrome termed
FIRES (febrile infection-related
epilepsy syndrome). “So far the
NORSE Institute has developed,
posted, and published a recommended diagnostic evaluation
for specialists, readily available
through the NORSE Institute
website,” said Hirsch. “One of
the first challenges for a new
disease is creating a name and
consistent definition for it. The
next is awareness—making sure
everyone knows about the disease or the condition’s definition.” The NORSE Institute has
been very successful in addressing these issues.

G E T T Y. C O M I L LU S T R AT I O N

chronicle

“NORSE shares some attributes
with FIRES, now defined as a
subset of NORSE, in which the
patient has a prior infection with
fever, usually a mild one,” said
Hirsch. He added that although
FIRES has traditionally been associated with children, it occurs in
adults as well.
Through the Wongs’ support,
the NORSE Institute sponsored
the first international conference on NORSE in Salzburg,
Austria, in 2017, where Hirsch
and his group of experts met
and later presented the consensus definitions. The definitions
were published in Epilepsia in
2018 and are accepted as standard definitions worldwide. A
roadmap of NORSE research
was published in Neurology
by Hirsch, Gaspard, and other
members of the NORSE Institute
medical advisory board. The
institute sponsored multiple
roundtable workshops with
international researchers
discussing the immunologic,
genetic, and clinical aspects
of NORSE, including ways to
determine the best treatments.
And in December 2019, the
NORSE Family Registry was
launched. This registry allows
families to provide retrospective information about NORSE
patients; it is intended to complement the ongoing prospective study of acutely ill NORSE
patients. The NORSE family registry is supported through a gift
to Yale by the family of Robert N.
Kohn, who also died of NORSE.
—Adrian Bonenberger

»

Behind the scenes at
“Diagnosis”
Twice a month, the “Diagnosis”
column appears in The New York
Times Magazine. In 1,300 words,
Lisa Sanders, MD ’97, HS ’00,
associate professor of medicine
at Yale School of Medicine (YSM),
untangles a case that has had doctors scratching their heads as they
sort through a patient’s symptoms for clues to the diagnosis.
“I’m interested in the diagnostic process, how you get from
puzzling symptoms to an
important diagnosis,” said
Sanders, who started writing
the column in 2002.
Since then her column has
spawned a TV drama, House,
which aired from 2004 to 2012;
provided material for her own
books; and recently became a
series on Netflix. At first, the
column appeared once a month
and Sanders did all the research
and interviews on her own. But
in 2016, when her editor asked her
for two columns a month, “I realized I needed help,” Sanders said.
She turned to the Office of
Student Affairs, which sent an
email inviting medical students to apply for an interesting
research opportunity. Sanders’s
first hire was Fatima Mirza, a
third-year student, who wrote
for the Harvard Crimson as an
undergrad and served as coeditor-in-chief of the Yale
Journal of Biology and Medicine.
A year ago, Sanders took on a
second assistant, Aishwarya
Vijay, a fourth-year student at
YSM, who wrote for the Yale

Daily News as an undergrad.
Mirza and Vijay make the first
pass at story ideas that come in
via email, at grand rounds, and
through the grapevine.
Another YSM graduate who
put heavy work into tracking
down appropriate patient stories
was Michael Gormally, MD ’19,
PhD. “Michael helped me set up
a system for me to keep track
of the patients I am planning to
write about,” said Sanders. “Not
a week goes by that I don’t benefit from his smart system.”
With the column’s increasing popularity and the debut
of the Netflix series in August,
emails have poured in, Sanders
said. “Right now, I get about
100 emails a day. Before, I got
maybe 100 a month.”
How do Sanders and her assistants decide what makes the cut?
First, there has to be a mystery.
Each column starts with
symptoms ranging from the
commonplace to the bizarre that
stymie the patient’s doctor or
doctors. They may order further
tests or consult with colleagues
as they seek a diagnosis. “You
know it’s a weird case if it’s in
my column,” Sanders said.
“Often, it’s a very rare presentation of a common disease,
and you want to look at something that has a happy ending,”
said Mirza. “If it doesn’t have a
happy ending, there’s some sort
of big lesson you can take from it
that can help other patients.”
“It’s easier to have a case
when there is one team or one
doctor that made the decision

Winter 2020

7

chronicle

online exclusive

Yale Journal of Biology
and Medicine has, at
long last, earned an
Impact Factor. This
means they’ll be
monitored to see how
often their articles
are cited by others, a
huge coup for the only
internationally recognized medical journal
edited and published
by students.
For more on YJBM, visit
ymm.yale.edu/yjbm

and can really focus and give a
full narrative,” Vijay added.
To find those cases, the team
sorts through thousands of tips
for the 24 that will make it into
the column each year. Then
they reach out to the doctor on
a promising case and obtain a
signed release to speak to the
patient and obtain medical
records. “Until you talk to them
you never get the full story,”
Mirza said. “You get a two- or
three-sentence synopsis from
their email and you don’t know
if it’s a real diagnosis.”

8
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The students then explain
how the reporting and writing process will unfold. “The
patients are usually ecstatic,”
Vijay said. “They want to get
the word out about what they
struggled with.”
After initial interviews and
a review of the medical records,
Mirza and Vijay pass their suggestions on to Sanders. And they

note that there are often false
starts. “Stories fall through all
the time,” Vijay said. “We get
halfway down the line and then
the medical records don’t work
out or the patient has decided
that they don’t feel comfortable.”
The irregular schedules of
medical students and a working
physician, and the unyielding
deadlines of a major newspaper
make for odd working hours.
Sanders and her two assistants
are rarely able to meet in person,
so they communicate by phone
and email. And they’re usually
multitasking. “We often have
multiple cases and a bunch on
the back burner,” said Vijay.
Once she’s chosen the cases for
her column, Sanders reaches out
to the patient and doctor for more
in-depth interviews. There may
be multiple doctors on the case,
but Sanders usually interviews
only the ones who made the diagnosis. Readers often ask how the
doctors could have missed what
seems in hindsight so obvious.
“Diagnosis is a process,”
Sanders said. “You have to go
through what everybody has
before you can look at what
nobody has.”
Sanders typically spends two
days on her first draft, then goes
over it twice more. Her columns
reach the Times on a Monday; by
Thursday of the following week
they’re online; and by the next
Sunday they’re in print.
“When I see it in the paper,”
she said, “I know it’s time to
write my next one.”
—John Curtis

a collection of recent
scientific findings

SCHOOLCHILDREN SHAPED
BY TEACHERS’ BIASES
A study co-authored by Yale sociologist Grace Kao, PhD, concludes
that first grade teachers’ racial and
gender biases about the abilities of
their students affects how those
students perform academically, as
well as how those students view
themselves and their abilities.
Kao’s study was published online
in January in the Du Bois Review:
Social Science Research on Race.

G E T T Y. C O M I L LU S T R AT I O N S & P H OTO S

KETO DIET BETTER
IN SMALL DOSES
According to the lead author of a
recent study, the keto diet’s effectiveness derives from its ability
to trick the body into burning fat.
Vishwa Deep Dixit, DVM, PhD, the
Waldemar Von Zedwitz Professor
of Comparative Medicine and professor of immunology, evaluated
the mechanisms by which the body
processes different types of food—
in this particular case, a diet’s low
carbohydrate content—and made
the unusual discovery.
Dixit warns, however, that the
keto diet works for only a limited
time period in mice, and that studies in humans are needed to find
out whether humans can safely follow the diet for months or years.

MEDICAL ERRORS DON’T PLAY
A ROLE IN MOST HOSPITAL DEATHS

BRIGHT START FOR YALE
ALUMNI HEALTH NETWORK
A new alumni health group, cofounded by Christine Walsh,
MD ’73, and Jamie Wells, MD, held
its inaugural meeting at the Yale
Club of NYC this winter. The Yale
Alumni Health Network (YAHN)
hopes to bring Yale alumni leaders together from all sectors that
touch on health and health care:
medical practice, academia, science, law, and finance.
Interested Yale School of Medicine
(YSM) alumni can find YAHN on
Facebook, Twitter, and LinkedIn.

Due to underlying disease, estimates of preventable deaths
of hospitalized patients may be
two to four times too high. The
YSM and VA Connecticut study
extrapolated likely numbers for
the United States from results in
European and Canadian hospitals.
Benjamin Rodwin, MD, assistant
professor of medicine, said that
more studies are needed, but the
notion that the quality of care in
hospitals is better than previously
assumed is indeed welcome news.

Winter 2020
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Short-term gains,
long-term losses
IN THIS ISSUE, Yale Medicine Magazine covers research at Yale School of
Medicine that extends the boundaries of what humankind knows about
inflammation—the body’s response to threat or infection. Our writers
explore the long history of physicians observing inflammation and also describe the physiology of inflammation—what current science understands
about the process of inflammation, its energy costs, and the role it plays
in wound repair and aging. Finally, we attempt to lay out the most current
progress being made in understanding why immune systems work the way
they do.
At stake is more than just the short-term benefits versus long-term
costs of inflammation. Many diseases and conditions are either caused or
influenced by malfunctioning immune systems—from lupus to Alzheimer’s
disease to diabetes and many more. Understanding how the immune
system works and the role inflammation plays will do more than answer
esoteric questions about disease—it will improve the quality of life for
people who are struggling every day with deadly ailments, and may even
save or extend lives.
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Inflammation:
part hero,
part villain
by christopher hoffman | otto steininger illustration
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Inflammation: part hero, part villain

The traditional approach
to inflammation is that
it’s bad and should be
suppressed, but recent
findings offer a more
nuanced view.

For many years, inflammation was considered one of
medicine’s chief enemies. Experts viewed it as a side
effect of illness and injury, a negative byproduct of the
body’s efforts to heal. One managed and banished it
whenever possible.
That view has undergone a major reassessment
over the last decade. Inflammation, it turns out,
isn’t always bad. In fact, researchers increasingly
believe that it plays a vital role in maintaining good
health. Some even believe inflammation is so central
to the body’s proper functioning that our understanding of physiology must be rewritten.
“It (inflammation) is a very natural state,” said
David A. Hafler, MD, the William S. and Lois Stiles
Edgerly Professor of Neurology, professor of
immunobiology, and chair of the School of Medicine’s Department of Neurology. “When you look
at the immune system, it has multiple roles.
The obvious one is fighting off infection. But the
immune system has also been co-opted by nature

14
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to be used in a number of different systems for
homeostasis. Inflammation is more than about just
fighting off disease.”
Some examples: The immune system acts at times as
a kind of cleanup crew that tidies up molecular messes.
Elsewhere, it performs such functions totally unrelated
to fighting microbes as pruning excess neurons in the
brains of small children—an essential part of brain
development. The immune system also helps regulate
the function of many organs, including the liver and
intestines. In doing all of these good things, it inevitably leaves residual inflammation.
a two-edged sword
While these insights recast inflammation as a more
positive component of a person’s health, they
also raise intriguing questions about how it may
cause illness later in life. Are such diseases as
cancer, for example, triggered when the immune
system’s maintenance and regulatory duties go

R O B E R T A . L I S A K P H OTO

awry, often in connection with a gene, and cause too
much inflammation?
“The immune system is a two-edged sword,” said
John MacMicking, PhD, an associate professor of microbial pathogenesis and of immunobiology, and a Howard
Hughes Medical Institute (HHMI) investigator. “Some
things help protect you. Some things put you in harm’s
way. Researchers are looking for the right balance.”
Inflammation has already been identified as a
culprit instead of just a side effect in many illnesses,
including multiple sclerosis (MS) and other autoimmune diseases. We have also learned that it plays a
role in so-called lifestyle illnesses and such conditions
as heart disease, obesity, and diabetes, said Akiko
Iwasaki, PhD, the Waldemar Von Zedtwitz Professor
of Immunobiology, professor of molecular, cellular
and developmental biology, and an HHMI investigator. It’s hard to think of any disease that does not
involve inflammation, Iwasaki said. That fact has some
researchers calling for a wholesale reassessment of
inflammation’s role in the body’s functioning.
“We still think in terms of normal physiology and
abnormal inflammation,” said the Sterling Professor
of Immunobiology and HHMI investigator Ruslan
Medzhitov, PhD, one of the world’s leading inflammation researchers. “That view is, I think, outdated.
There’s no modern framework to replace that view.”
Medzhitov and his lab are hard at work building
that scaffolding. He argues that inflammation is as
central to understanding physiology as are hormones.
Once the initial work is complete, the next stage will
be to try to find ways to turn inflammation on and off
to treat or forestall disease, he said. He estimates we
are about halfway to mapping the basics but only 10%
of the way toward fully understanding how inflammation works.
“It’s clear that inflammation is not just about infection,”
he said. “It’s not just a response to injury. It has multiple
other job descriptions, multiple other functions that are
involved also in what we call normal physiology.”
In a pioneering step, the medical school has
incorporated Medzhitov’s findings into its curriculum, teaching future doctors that inflammation
is an integral part of both health and sickness, not
simply a side effect. As research attaches ever greater

David Hafler says inflammation
is more than a defense system to
fight infection—it’s part of how a
healthy body maintains homeostasis, such as when it prunes
excess neurons in the developing
brains of children, or when it occurs in the liver and intestines.

importance to inflammation, Yale is considering the
establishment of an institute devoted exclusively to its
study, according to Medzhitov and other researchers
at the school. Understanding the role of inflammation
in the body at the molecular level could pave the way
for a new generation of pharmaceuticals and treatments. Because inflammation accompanies nearly
every illness and disease, the potential for new developments is enormous.
“If you are infected, inflammation can even be a
good thing, helping provide additional signals that
alert the host to the presence of microbial pathogens
and recruiting immune cells to the site of infection. However, you need to turn it off once the infection is resolved to avoid excessive tissue damage,”
MacMicking said. “Is there a way to do that? Can I take
a pill that helps reduce the inflammatory burden?”
the role of cytokines
On a basic level, our understanding of inflammation
hasn’t changed, Iwasaki said. Inflammation from a
broken ankle or a bronchial illness, for example, is
the body’s way of summoning the immune system to
restore homeostasis. Too much inflammation in and of
itself can kill by, for example, flooding the lungs with
fluid or causing dehydration.
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Inflammation: part hero, part villain

His lab compared spinal fluid from healthy medical students and patients with MS. Unsurprisingly, the fluid
from MS patients was inflamed—but so was that of the
healthy medical students. “We had a very hard time
telling the difference between MS spinal fluid and normal spinal fluid,” he said. That’s because cytokines, in
addition to fighting disease, also help regulate the nervous system in relation to synaptic connections, fluid
absorption, and other functions, he said.

Carla Rothlin wants to know
about mechanisms that set or
limit the magnitude of the body’s
immune response—how a body
transitions from defense to
wound repair, and why.

Now we understand that inflammation can be both
a cause and an effect, Iwasaki said. Obesity and diabetes are examples, she continued. When people become
overweight, their fat cells become bigger. Immune
system cells called macrophages, whose job is to maintain homeostasis, sense something is wrong, and they
deploy disease-fighting small proteins called cytokines
against the cells, creating inflammation. While the tipping point remains unclear—it appears to vary from
person to person—the resulting inflammation can lead
to diabetes and heart disease. Exactly how that happens
requires further study, said Iwasaki. “We just know that
if we can block these macrophages from firing, we can
prevent the disease from happening,” she said.
Another example is Alzheimer’s disease, Iwasaki
said. Research indicates that an immune reaction to
amyloid plaques in the brain may contribute to the
dreaded illness. According to the model, macrophages
interpret crystal-like plaques in the brain as foreign
objects and begin secreting cytokines that attack
them, which leads to inflammation and destruction of neurons culminating in dementia. Ultimately,
inflammation may also play a role in such behaviors as
depression and suicide, she said.
Hafler, an expert on MS, cites yet another example of
the double duty performed by inflammatory cytokines.
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keeping the microbiome healthy
There’s another potential source of sickness-inducing
inflammation: the human gut. Researchers increasingly think that inflammation in the digestive tract
may be the point of origin of a variety of diseases,
including neurodegenerative illnesses like Parkinson’s.
They are also coming to believe that a healthy microbiome—the billions of bacteria in the gut that help us
process food—may be key to avoiding that potentially
disease-inducing inflammation.
Noah Palm, PhD ’11, FW ’15, assistant professor of
immunobiology, and his lab team are probing the connections between the microbiome, inflammation, and
disease. The microbiome is exquisitely sensitive, Palm
said. Changes in diet, or even something as seemingly
benign as living with a dog, significantly alter the
teeming microbial communities that populate our guts,
he said. As the Western environment has become more
antiseptic and most people’s diets contain fewer plants
and more processed foods, the makeup of our gut
microbiome has changed, and its diversity has declined
significantly. At the same time, the incidence of certain inflammatory illnesses and conditions—allergies,
obesity, heart disease, diabetes—has exploded. Is there
a connection?
“In my lab, we are trying to make the transition from
correlation to causation,” said Palm. He has already
begun to establish potential causation in certain illnesses, specifically inflammatory bowel disease (IBD).
He and his lab assistants have found that when microbiome material from an IBD sufferer is inserted into
an otherwise healthy mouse, the mouse will develop a
disease that looks similar to human IBD. While genetic
factors may also be involved, these findings indicate
that particular bacteria may trigger IBD in at least a
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subset of patients. Palm’s research has a long way to go,
but it could ultimately lead to individualized treatments
designed to maximize microbiome health and stave off
disease-inducing inflammation.
a new approach to antibiotic resistance
The expanded understanding of inflammation in the
gut and how it is induced could also one day address
one of medicine’s biggest long-term challenges: antibiotic resistance. Jorge Galán, PhD, DVM, the Lucille
P. Markey Professor of Microbial Pathogenesis, professor of cell biology, and chair of the Department of
Microbial Pathogenesis, said his lab studies “in detail”
intestinal tract diseases—especially salmonellosis. The
long-held view was that the inflammation resulting
from Salmonella infection, which makes you sick, was
caused by the immune system’s attacking the pathogen.
But “we now know that this is not the case,” Galán said.
Nutrients are scarce in the gut, Galán added. In
order to make those nutrients available, Salmonella
and similar pathogens must induce inflammation.
That’s not easy because the immune system is tamped
down in the gut; otherwise recognition of the bacteria in the microbiome would trigger a chronic state
of inflammation. “Salmonella needs inflammation,”
Galán said. “Its stomping ground is the gut. Now it’s
got a problem. It needs inflammation in a place where
it’s not easy to trigger it.”
Salmonella meets this goal by injecting proteins
that trigger inflammation, thereby producing the
nutrients it needs to survive, Galán said. He has on a
table in his office a clear block containing an image of
the pathogen’s microinjection device, a gift from his
students. Most of the time, the resulting inflammation
isn’t enough to make a person sick because the pathogen uses its own mechanisms to turn it off; it’s when
inflammation gets out of control, which is rare, that
one develops the classic symptoms of salmonellosis.
“That is what is so cool about inflammation,” Galán said.
“There are so many ways to trigger it.”
Galán’s insight potentially creates a new treatment pathway. Instead of killing the pathogen with a
classic antibiotic, you can try to formulate a targeted
drug that simply shuts off the microinjection device
inducing the inflammation, he said. “You gum up the

1980s data demonstrated that taking
aspirin lowered the risk for cardiovascular disease. They expanded
that research to include cancer, and
determined that aspirin could lower
mortality there as well, acting as a
chemopreventative therapy, according to Charles Fuchs.

bacteria,” Galán said. “You are preventing the bacteria
from causing disease, which is a totally different concept. Certainly the evolutionary process that leads to
antibiotic resistance would be slowed significantly.”
The promise of a deeper understanding of inflammation and its roles in sickness and health is significant, potentially paving the way for individualized and
less invasive treatments that work in harmony with
the body, researchers say. It may well boil down to
learning how to turn inflammation from on to off.
“Can we uncouple the beneficial from the harmful
effects?” MacMicking said. “Find new molecular targets that mount effective antimicrobial responses but
avoid the non-collateral damage. Cytokine signaling
turns on hundreds of genes—is there a way to pick and
choose downstream host responses we’d like to elicit
and quieten those we wish to avoid?” MacMicking and
his fellow Yale researchers are working to find out.
/yale medicine magazine
Christopher Hoffman is a frequent contributor to Yale Medicine
Magazine.
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Studying autoimmunity
Researchers hope that the Colton Center for Autoimmunity at
Yale will yield results over the next 10 years.
by john curtis | otto steininger illustration
Throughout his career at Yale, Joseph E. Craft, MD, HS ’80,
FW ’85, has studied autoimmunity, specifically systemic
lupus erythematosus. Now he’s heading a new project that
will span the university, encouraging researchers from
disciplines inside and outside medicine to seek ways to
move existing knowledge about the more than 80 autoimmune diseases from the laboratory to the clinic.
“The goal is to take what we know about autoimmunity
from our research at Yale and what we have learned from
others and move those ideas into practical applications,”
said Craft, the Paul B. Beeson Professor of Medicine
(Rheumatology) and professor of immunobiology. “Many
of the proposals will come from immunologists, but by
no means is it meant to be restricted to experts in autoimmunity, nor is it meant to be restricted to experts in
immunology. We want the best ideas: things that may be
novel, things that may be untried and untested, things
that may be pie in the sky.”
The Colton Center for Autoimmunity at Yale is an
outgrowth of an initiative that began at NYU Langone
Health in 2013. The Judith and Stewart Colton Center for
Autoimmunity was launched to find new ways of diagnosing and treating autoimmune diseases. Although centered
at NYU, the program has recruited researchers and clinicians throughout the scientific community. Creating a
satellite center at Yale with Craft in charge was an obvious
choice—he sits on the NYU center’s advisory board.
The satellite center at Yale will receive funding for up
to 10 years. In its first year, Craft said, he hopes to fund
about eight proposals. “The idea is to use funds every year
to invest in ideas to develop intellectual property,” he
said. “That’s the first step to getting those into translatable initiatives.”
Research proposals from across the university are
welcome, Craft said. “You don’t have to be an expert
in autoimmunity to have a good idea. It could be from

engineering, the Faculty of Arts & Sciences, chemistry,”
he said, adding that faculty at all levels are encouraged to
apply. “That only enhances the ability of the program to
get things done. Biomedical engineering has been very
successful in thinking about ideas on how to treat cancer.
If they can bring those ideas to autoimmune disease, that
would be great.”
An advisory committee of four faculty in immunobiology, two academics from outside Yale, and three private
sector members with experience in technology transfer
and immune-mediated diseases will review grant applications. The committee will meet once each year in person and throughout the year in videoconferences.
The application process, Craft said, will be streamlined. “We would like to shorten that to a couple of
months and make the hurdle for applying relatively
simple,” he said. “Putting the idea on paper ideally would
be done in a day or two. Our goal is to eliminate the
bureaucracy and eliminate the timing.”
The new center also fits in with the University Science
Strategy Commitment (USSC), said Michael C. Crair, PhD,
the William Ziegler III Professor of Neuroscience, professor of ophthalmology and visual science, and vice provost
of research for Yale University. He will serve as an ex
officio member of the center’s advisory board. The USSC
will invest in strong areas of science at Yale, specifically
inflammation, neuroscience, data science, energy science,
and environment.
“Inflammation is one of the top areas where we’d like
to build, and autoimmune is one of the pieces within the
broad area of inflammation,” Crair said. “We want to
make sure that what we are doing in autoimmunity is
coordinated with what we are doing in all the inflammation sciences.” /yale medicine magazine
John Curtis is a frequent contributor to Yale Medicine Magazine.
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Ketostasis:
nature’s sweet spot
by sonya collins | otto steininger illustration

Ketostasis: nature’s sweet spot

Glucose plays a
complex role in immune
system health
For followers of popular science news—or of the latest diet
craze—the term “intermittent fasting” is decidedly trending. Each new mention of the eating plan brings with it
more revelations about the health benefits it could offer.
In the last six months alone, new studies have tied fasting to reduced risk of diabetes, heart disease, and a host of
chronic inflammatory diseases. Periodic fasting may also
improve symptoms of multiple sclerosis and inflammatory
bowel disease. One study found that a 24-hour fast boosts
regeneration of intestinal stem cells in aging mice.
But what’s behind all these potential benefits of
occasionally going without food? Yale research suggests that sugar deprivation gives fasting its many virtues. It may halt or mitigate inflammation that leads
to or exacerbates numerous illnesses. And it could be
that each of the potential health benefits of eliminating
sugar is born of a different mechanism.
feed a viral infection, starve a bacterial one?
When colleagues Andrew Wang, MD, PhD, HS ’13,
FW ’17, and Ruslan Medzhitov, PhD, were discussing
how they feed their kids when they’re sick, they started
to wonder what was behind the old adage, “Starve a
fever, feed a cold.”
“All animals—from worms, to flies, to dogs, to us—do
this. When we get acutely infected, we lose our appetite,
and people have wondered for a long time why that might
be,” said Wang, who is an assistant professor of medicine
(rheumatology) and of immunology.
The two wanted to find out the potential benefits of
fasting during an illness. In their 2016 study, published
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in Cell, when they force-fed an animal that was fighting
listeriosis—a bacterial infection—the animal died. On the
other hand, feeding an animal battling the flu—a viral
infection—helped nurse it back to health.
When the researchers broke the food down into its key
components—protein, fat, and sugar—they found that
sugar is the active ingredient. Mice that had viral infections needed glucose to adapt to the stress brought on by
antiviral inflammation and to prevent stress-induced cell
death. In bacterial infections, however, glucose prevented
ketogenesis, which was necessary to counteract the oxidative stress of antibacterial inflammation.
Still, Wang said, “As a doctor, I’m hesitant to simply
say, ‘If you think you have a bacterial infection, starve
yourself, and if you think it’s viral, don’t.’ ”
And Wang has good reason to hold off doling out
that advice. The role of glucose in inflammation is far
more complex. New research suggests that glucose
deprivation before flu infection may in fact prepare the
body to fight it. While glucose after flu infection promotes adaptation to inflammation, a November 2019
study in Science Immunology co-authored by Vishwa
Deep Dixit, DVM, PhD, the Waldemar Von Zedtwitz
Professor of Comparative Medicine and professor of
immunobiology, suggests mice already in ketogenesis
are better equipped to fight the flu once it hits.
In the study, mice that were on the high-fat, lowcarbohydrate ketogenic diet when they contracted the
flu were more likely to survive the illness than those on a
normal high-carb diet. The extremely low-carb diet, the
study found, activates a group of T cells in the lungs not

previously linked to the immune system’s response to
influenza. The T cells step up mucus production in airway
cells and trap the virus.
While the studies point to opposing roles for glucose
in viral inflammation, they also asked different questions.
“Our 2016 study,” said Wang, “asks why animals eat
less when they have the flu. So, we fed them after they
were infected to see what impact that would have. [This
new study] asks, ‘If an animal is in a ketotic state, how
does it affect response to flu infection?’ I think what is
clear from both studies is that the metabolic state of the
organism in an infection—before and during, and probably during recovery—is a critical determinant of the
organism’s overall outcome in that infection.”
Glucose has a role in parasitic infections, too. Wang
and Medzhitov explored this relationship in a 2018
study published in Proceedings of the National
Academy of Sciences (PNAS). When they blocked glycolysis in mice with malaria, the mice didn’t go on to
develop cerebral malaria.
The glucose deprivation didn’t make the mice resistant to malaria. In fact, in both groups, parasite burden,
neuroinflammation, blood-brain barrier permeability,
and anemia were the same. But, blocking glucose made
mice more tolerant of the disease. Or maybe, the study
authors suggest, glycolysis inhibition made the parasites
themselves less harmful. Either way, fewer microthrombi (tiny blood clots) formed in the brains of those
mice, preventing the spread of the infection to the brain.
burn fat, slow aging
Of course, inflammation isn’t only an acute reaction to
a new infection. Ongoing inflammation is implicated in
nearly all diseases of aging. If modulating glucose can
change the course of acute infection, could it also interfere with the lifelong process of aging?
“Most of the cells in the body run primarily on glucose,” said Dixit. “So, we wanted to know what happens
when glucose is limited.” The answer sheds more light
on the various health benefits of fasting and low-carb
diets like the ketogenic diet.
When the body doesn’t have glucose for fuel, it burns
fat for energy. This process occurs in fasting, starvation,
and in endurance exercise after sugar stores are used up.
It also happens on a low-carb diet.

The brain and heart are the biggest consumers of
the body’s energy. But when the body turns fat into
long-chain fatty acids, they can’t cross the blood-brain
barrier. So, the body converts those into short-chain
fatty acids, specifically a ketone metabolite called betahydroxybutyrate, for the brain’s use.
When the body runs on fat for fuel, Dixit and his
team wondered, what happens to immune cell function?
Macrophages—mobile white blood cells that gather at
infection sites—run on glucose when they are inflamed.
“If macrophages aren’t seeing glucose,” Dixit added,
“but are exposed to alternate fuels instead, how would
that affect their activation state?”
What Dixit and his team found was that beta-hydroxybutyrate can block an inflammatory protein complex
called the NLRP3 inflammasome. Now, NLRP3 isn’t all bad.
It plays an important role in triggering inflammation in
acute infection. But, Dixit explained, “If it remains chronically activated, it can lead to multiple chronic diseases and
it’s implicated in the overall process of aging.”
When researchers gave beta-hydroxybutyrate to
NLRP3-inflamed mice, the ketone metabolite blocked the
inflammasome, and the mice did not go on to develop
several age-related chronic diseases.
The findings may help explain why popular diets
like intermittent fasting and keto bring health benefits
beyond weight loss. “Because when one is fasting,”
Dixit said, “the body has to burn fat, and the metabolites that are increased in this process can potentially
reduce inflammation.”
just a spoonful of sugar
This deeper understanding of sugar’s role in inflammation could lay the groundwork for both dietary recommendations and medications that regulate glucose in
various types of inflammation.
But that doesn’t mean sugar is all bad. “The appropriate amount of everything is what we require,” said Dixit.
There’s not one diet that fits all. “Different types of
inflammation require different things,” said Wang. “So,
you have a lot of moving parts, and figuring out the
combination that gives you the best clinical results is
not trivial.” /yale medicine magazine
Sonya Collins is a frequent contibutor to Yale Medicine Magazine.
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Another use for aspirin

A versatile remedy also a potential treatment for breast cancer.
by john curtis | otto steininger illustration
In ancient times physicians extracted from the bark of
the willow tree a substance—salicylic acid—that reduced
fevers, inflammation, and pain. By the mid-19th century, a French chemist had mixed the acid with acetyl
chloride to form acetylsalicylic acid, the compound that
Bayer marketed in 1899 as aspirin.
Over time aspirin transcended its original uses, and
by the 1970s and 1980s it was seen as a treatment for
stroke and heart disease. During the 1980s physicians
and researchers also saw that it could fight cancer.
By 1991, they’d found that aspirin lowered the risk of
colorectal cancer, and subsequent studies linked it to a
lower risk of other cancers.
Physicians at Yale are helping to figure out whether
aspirin can keep breast cancer from recurring in
women who have already gone through surgery, radiation, and chemotherapy.
“There’s an overwhelming amount of data that suggests that taking aspirin may be beneficial, and that
aspirin is safe enough for the majority of people to take
daily,” said Neal Fischbach, MD, assistant professor of
clinical medicine (medical oncology), who’s leading
the trial at Yale.
The Aspirin for Breast Cancer (ABC) Trial was
launched in Boston, sponsored by Brigham and Women’s
Hospital and Dana-Farber Cancer Institute. The study
hopes to recruit 3,000 patients between 18 and 70 who
have had breast cancer, haven’t used aspirin in the past
month, and whose breast cancer has not recurred.
Previous studies, said Fischbach, have found a
reduced risk of recurrent metastatic breast cancer in
those who take aspirin. “Aspirin might not be preventing cancer,” he said, “but in those who get cancer, it
may prevent cancer from spreading.”
Aspirin’s anti-inflammatory properties, Fischbach
said, inhibit the enzyme cyclooxygenase. “That pathway is important in production of many inflammatory mediators which have a lot to do with cancer cell
growth and metastasis,” he said. “For the same reason

that taking anti-inflammatories may be good to reduce
joint inflammation and pain, they may also inhibit
metastatic spread and growth of cancer cells.”
Among aspirin’s drawbacks are the risks of gastrointestinal bleeding and hemorrhagic stroke in some
patients. And, Fischbach said, prior studies just aren’t
robust enough to recommend aspirin to prevent the
onset or recurrence of cancer. The only such recommendation to date came in 2015 when the National Cancer
Institute said that in certain patients, aspirin could prevent colorectal cancer and cardiovascular disease.
Charles Fuchs, MD, MPH, the Richard Sackler and
Jonathan Sackler Professor of Medicine (Medical
Oncology), director of Yale Cancer Center, and physician-in-chief of Smilow Cancer Hospital, traced original studies of aspirin and cancer to the 1980s.
“That is when the data of aspirin and its ability to
affect cardiovascular risk came to the forefront,” he
said. “A lot of those studies that were designed to look
at cardiovascular risk also started to look at cancer risk,
finding that [aspirin] did reduce cancer mortality.”
Fuchs and colleagues found that aspirin could affect
the growth of colon cancer cells in the lab. Clinical trials further found a link between taking aspirin regularly and a reduced risk of developing colorectal cancer.
“That has led a number of policy-making organizations
to conclude that aspirin is a chemopreventive therapy
for colon cancer,” he said.
So far Fischbach has recruited 20 patients for the
breast cancer trial. For five years, half will receive
aspirin and half will receive a placebo that looks and
tastes like aspirin. Ideally, Fischbach said, researchers
would like to see a reduction in cancer recurrence of
between 25 and 50%.
“We have detected a glimmer that aspirin may be
good for cancer,” he said, “but we don’t have the really
robust prospective studies.” /yale medicine magazine
John Curtis is a frequent contributor to Yale Medicine Magazine.
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Untangling the web of
autoimmune disorders
When a person develops certain autoimmune disorders,
others often follow in their wake. Figuring out why, and how
to stop the deterioration, are top priorities for scientists.
by steve hamm | otto steininger illustration
Seven years ago, Fatiha began to experience joint pain
and swelling of her hands. A doctor diagnosed her
with Sjögren’s syndrome, an autoimmune disease.
Three years later, the joint pain flared up and was
accompanied by a severe rash and sudden hair loss.
Fatiha, 32, who asked for her last name to be withheld,
could barely walk. The diagnosis was lupus, another
autoimmune disease.
Still later, she was diagnosed with rheumatoid
arthritis. In spite of her illnesses, the Trumbull, Conn.,
resident works at a restaurant and is studying computer science at the University of Bridgeport. “I was
never sick before in my life. Then one day everything
changed,” she said.
It is not unusual for people who develop one autoimmune disorder to experience one or more additional
ones. Figuring out why this happens is challenging for
clinicians and medical scientists. It’s a tangled web of
causes and effects.
But experts in the field believe that the knowledge
they gain from treating such patients combined with
advances in laboratory research will not only bring
relief to countless people around the globe but will
also help scientists better understand the fundamental
mechanisms of inflammation and the immune system.
While tremendous progress has been made in
treating some autoimmune disorders, doctors are

frustrated by the slow progress in treating other
disorders and in cases where multiple disorders or
unusual clusters of symptoms occur. “We have to
understand the mechanisms, especially the immune
mechanisms. But we also have to understand deeply
what’s going on with an individual patient. It’s a form
of precision medicine,” said Insoo Kang, MD, an associate professor of medicine (rheumatology) at Yale
School of Medicine, who is now treating Fatiha.
“This is what we hope to accomplish over the next five
to 10 years.”
Autoimmunity occurs when the immune system
loses tolerance of the body’s own tissues and behaves as if they are infected with a pathogen. In
addition, some researchers believe autoimmunity
may occur when the immune system overreacts to
a pathogen that has entered the body and attacks
healthy tissues.
Typically, autoimmune diseases are treated with
therapies that depress the immune system—an
approach that leaves patients vulnerable to viruses,
bacteria, and other pathogens. “The immune system
can be protective or pathogenic. It’s the classic metaphor—the double-edged sword,” said Jordan Pober,
MD ’77, PhD ’77, FW ’78, professor of immunobiology, the Bayer Professor of Translational Medicine and
pathology and dermatology.
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Untangling the web of autoimmune disorders

Some of the more common autoimmune diseases
include rheumatoid arthritis, which attacks the joints;
lupus, which affects skin, joints, and kidneys; multiple
sclerosis, which attacks the nervous system; and
inflammatory bowel disease.
Autoimmune diseases are typically caused by mutations in multiple genes, but they can be triggered by
environmental factors and stress. Inflammation is
closely associated with autoimmune disorders. Most
often, it’s a symptom of the disorders, but sometimes
it’s a trigger. “Immune diseases are very complex. You
can have the wrong genes but need also the wrong
microbiome, diet, or environmental factors,” said
Martin Kriegel, MD, PhD, FW ’06, an associate professor adjunct of immunobiology.
Tumor necrosis factor (TNF) blockers are being used
successfully to treat rheumatoid arthritis and other
autoimmune diseases, including psoriatic arthritis,
ulcerative colitis, and Crohn’s disease. However, lupus
and some other diseases are not as well understood.
People with lupus seem to be particularly susceptible
to developing additional diseases.
Researchers believe that a malfunctioning thymus
may cause some people to have multiple diseases, said
Kriegel. The thymus is instrumental in the maturation of T lymphocytes (T cells), which are essential for
fighting pathogens throughout the body. Sometimes,
because of genetic defects, the T cells aren’t taught how
to distinguish between pathogens and normal cells. In
other cases, researchers suspect that checkpoints in
the lymph nodes and spleen, where immune responses
are typically launched, are faulty, leading to patients
having more than one disorder.
The causes and manifestations of autoimmune diseases are so complex that researchers struggle to find
the best ways to discuss them. Kang describes a “rainbow spectrum” of disorders in which causes and effects
overlap. Often, several gene mutations are shared by
multiple disorders. Meanwhile, Andrew Wang, MD,
PhD, HS ’13, FW ’17, assistant professor of medicine
(rheumatology) and of immunobiology, refers to “constellations” of disease. “If we’re honest with ourselves,
we recognize that patients with complicated inflammatory diseases can’t all be lumped together and all treated
the same,” he said.
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One of his patients, Lois Walters, a retired postal
worker in Hamden, Conn., was diagnosed with lupus
more than a decade ago, yet her symptoms, including
fatigue, joint pain, and skin rashes, didn’t respond well
to traditional therapies for lupus. After Wang became
her clinician four years ago, he tried a different strategy. He recognized that Walters essentially suffered
from her own personal version of lupus, so he broke
from conventional therapies and treated each of her
symptoms separately. It’s working. “This is the best
I’ve felt in a long time,” said Walters.
Wang believes that a new approach will be required
to address the complexities of autoimmune disorders.
Today, many of the successful therapies target immune
mediators, the signals that immune cells make to tell
the body there’s a problem. He believes that an alternative approach is to target the metabolic programs
that support the immune cells.
Wang said research breakthroughs will be essential
in dealing with these complex illnesses, but so will
old-fashioned doctoring: “It’s important to be mindful of the particular constellation that your patient
might have, and it’s important to listen to the patient
because they’ll tell you what’s wrong with them.” /
yale medicine magazine
Steve Hamm is a frequent contributor to Yale Medicine Magazine.

Getting warmer: thermoregulation
and inflammation
The human body has a number of innate responses to infection that include
heating the affected part of the body, or cooling it down. Yale School of
Medicine researchers are looking hard at the causes behind both.
The body survives infection in one of two ways:
resistance or tolerance. In resistance, the body
uses its resources to mount an all-out war
against the invading threat and eliminate it. In
tolerance, rather than spending its resources
on an attack, the body downshifts into “powersaver” mode where it rides out the infection.
During this time, trade-offs are made. Appetite
loss in sickness, for example, allows the body to
turn its energy away from food metabolism and
conserve strength for weathering the illness ahead.
And body temperature regulation, researchers are
learning, may also be a key trade-off when surviving an infection is the body’s top priority.
“The idea of using temperature to modulate
metabolism and affect immunity is not new, it’s
just not understood,” said Andrew Wang, MD,
PhD, HS ’13, FW ’17, assistant professor of medicine (rheumatology) and of immunobiology.
Ancient Egyptians used cryotherapy to treat inflammation as early as 2500 BCE. The Edwin Smith
Papyrus, the oldest known medical text, dated
3500 BCE, mentions cold therapy multiple times.
More recent research has begun to disassemble
the mechanism behind thermoregulation’s immunological success. “It turns out we have to spend a
considerable amount of energy defending our body
temperature,” said Wang. Saving that energy could
help the body enter tolerance mode.
In a study published in Cell in 2019, Wang and
his colleagues examined a hormone (growth
differentiation factor 15 or GDF15) that further
illuminates the role of metabolic regulation in
infection tolerance. In mouse models of both bacterial and viral sepsis, GDF15 was crucial for survival—which suggested its value isn’t measured

by helping the immune system attack a specific
type of invader. In fact, the hormone is triggered after the body launches an inflammatory
response. The hormone didn’t reduce pathogen
levels in mice compared to those in which GDF15
was blocked, either.
Researchers suspected that the hormone
doesn’t help the body resist infection at all.
Rather, it helps the body tolerate the inflammation that is necessary to fight it.
“In an overwhelming infection like sepsis,
where inflammation becomes a big problem,
the tolerance approach—rather than resistance
—can be beneficial,” said Ellen Foxman, MD,
PhD, FW ’15, assistant professor of laboratory
medicine and immunobiology.
The researchers identified physiological
changes that seemed to shift the mice into
tolerance mode. For one, GDF15 protected the
heart from injury in sepsis. It also maintained the
body’s temperature. Mice in which the hormone
was blocked suffered hypothermia—a serious
problem in sepsis patients.
According to Wang, it will be very important
to understand how metabolism is controlled to
increase resistance to disease. Cryopreservation and other states of suspended animation
are extreme examples of “power saver” modes
that confer maximal tolerance to inflammatory
insults. “Animals that hibernate are extraordinarily resistant to stress, trauma, infection, and
most inflammatory injuries,” said Wang. “There’s
tremendous interest in seeing how that works.”
—Adrian Bonenberger
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Why most
heads don’t swell

(from pride or infection)

by christopher hoffman | otto steininger illustration

30 ymm.yale.edu

Why most heads don’t swell

Some places in
the body don’t suffer
from inflammation
as a response to
intrusion.
The brain and
spinal cord are
among them.
When it comes to inflammation, not all organs are
created equal.
Some—including the brain and the spinal cord
—are privileged. By that immunologists mean that it
is very hard to produce inflammation in them. Why?
Because these organs have very few immune cells.
It’s difficult for them to get in, and the organs have
inhibitors that turn off immune cells that do manage
to gain entry.
“There may be limits to immune invasion and having immune cells migrate en masse into them [privileged organs] even though they can enter in small
numbers as part of ongoing immune surveillance,”
said John MacMicking, PhD, associate professor of

32 ymm.yale.edu

microbial pathogenesis and of immunobiology at Yale
School of Medicine, and a Howard Hughes Medical
Institute investigator.
On one level, this exclusion of immune cells makes
sense. The brain and spinal cord, unlike skin or the
liver, cannot regenerate themselves. Plus, there is
no backup system for the brain and the spinal cord,
unlike, for example, the kidneys. Once brain cells
are gone, they are gone forever. The last thing you
want is the body’s powerful immune system rampaging through the brain, triggering neuron-destroying
inflammation as it fights infection.
“In one sense, cells of the brain like neurons
may be less well equipped to deal with some of the

toxic products generated during inflammation,”
MacMicking said.
The good news is that it’s difficult for diseases to
get into the brain and the spinal cord. But what happens when it does? Even worse, what if that disease is
cancer? This is one of the reasons that treating brain
carcinoma is so challenging.
As if that isn’t bad enough, doctors face another
challenge with brain tumors: the blood-brain barrier.
It’s a thicket of cells that screens out immune cells
as well as microbes, said Lieping Chen, MD, PhD, the
United Technologies Corporation Professor in Cancer
Research and professor of immunobiology, of dermatology, and of medicine (medical oncology). The
blood-brain barrier is a good thing in that it keeps
illness out of the brain, but once again represents
a double-edged sword, Chen said. The barrier also
makes getting cancer medication into the brain difficult, said Chen, the co-leader of cancer immunology
at Yale Cancer Center.
“There’s a block,” Chen said. “It protects the brain
from most trouble, but it also makes it more difficult
to treat brain cancer.”
The blood-brain barrier, however, is not rigid and
unchanging. It can contract or expand. Researchers
have learned to trick it to expand, increasing the
amount of administered medicine that gets through
to as high as 40%, Chen said.
Once medicine is inside the brain, clinicians confront an additional challenge: keeping inflammation as
tamped down as possible to avoid damaging delicate
neurons, Chen said. “If you overdo it a little, you damage the brain,” he said. Understanding and one day
learning to control inhibitors that block immune cells
will help make treatments more effective, he said.
Recent research, meanwhile, has shown that the
blood-brain barrier is not as absolute as once believed,
according to MacMicking. “Immune cells do get into
the brain and look around,” he said. “The idea of
an impermeable, unforgiving physical structure is
more of a conceptual model than a functional one.”
That does allow the cells to initiate inflammatory
responses to disease, including cancer, he said.
Spinal cancers, meanwhile, are very rare and inflammation likely plays a role in them as well, MacMicking

and Chen said. “We know that inflammation, along
with genetics, is an underlying cause of another central
nervous system disease, multiple sclerosis [MS],” said
David Hafler, MD, chair of the Department of Neurology,
the William S. and Lois Stiles Edgerly Professor of
Neurology, and professor of immunobiology. An overly
robust autoimmune response leads to inflammation
when B cells tell T cells to attack the nervous system,
Hafler said. This process causes inflammation predominantly in the white matter of the brain and spinal cord.
The result is somewhat akin to the insulation being
stripped from an electrical wire.
“If you deplete the B cells, you stop the disease,”
said Hafler, an MS expert.
As Yale researchers close in on a better understanding of inflammation (or a lack thereof) in the
brain and spinal cord, conditions like MS and other
nervous system disorders or diseases may soon be
diseases of the past. /yale medicine magazine
Christopher Hoffman is a contributor to Yale Medicine Magazine.
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A new dimension to
intestinal surgery
One doesn’t often think of the intestines when thinking
about how 3D printing can assist with surgery or medicine.
John Geibel is looking to change that.
by adrian bonenberger | otto steininger illustration
Long considered one of the worst abdominal injuries,
intestines damaged by trauma or illness are almost
impossible to heal, and the injuries are fatal under certain circumstances. New technology may change that:
3D printing intestines from a subject’s own cells is fast
approaching commercial viability. And John Geibel, DSc,
MD, MS, FW ’88, professor of surgery (gastrointestinal),
of cellular and molecular physiology, vice chair of the
Department of Surgery, and director of surgical research,
is at the forefront of efforts to bring 3D-printed intestines
to market.
“Imagine, God forbid, you’ve been stabbed, or shot, as
often happens during war, or you develop some condition
that damages your intestines [radiation treatment, traumatic injury, or genetic abnormality that reduces functional intestine]. Soon, we’ll be able to fix that,” said Geibel.
Fixing pieces or lengths of intestine using 3D printing was something Geibel had considered, but it wasn’t
until he partnered with a company called Organovo
that he had the equipment to begin trials. Initial testing was promising, with lengths of intestine holding
up well to volume and pressure, so he decided to push
the limits, and developed a procedure capable of printing intestines even faster.
“The key to commercial viability with this process
is being able to make durable pieces of intestine that
won’t rupture, in a short enough timeframe that the
patient can benefit from it quickly. We think we have
such a procedure,” said Geibel.
Drawn to the intestine partly because of his surgical
focus on gastroenterology, Geibel said that focusing on

printing this particular organ provides another advantage to people looking to bring it online quickly as a
therapeutic option: its relative simplicity.
“The heart has seven cell types with multiple chambers,
multiple valves. The kidney has 26 different cell types and
2 million nephrons, not counting connective tissue and
vasculature. The intestines have seven cell types,” Geibel
said. “Furthermore, if you implant a piece of intestine
grown outside the body, that intestine will actually integrate into the rest of the system, so it can absorb nutrients
and be more than just a length of flexible tubing.”
The absorption of nutrients is one of the key difficulties for people suffering from diseases, conditions,
or injuries that affect the intestine. Initial trials have
been very promising, and 3D-printed intestinal sections that have been implanted to plug holes or cuts
made in healthy intestines in a laboratory setting have
been successful in animal models.
Although there are troubling technical aspects to
forming viable lengths of intestine, Geibel feels that his
technique addresses all concerns. Now, he’s working with
ways to print the intestine faster while also strengthening
the printed organ so that it can endure the vast amounts
of liquid, salts, nutrients, and waste products it will be
expected to carry. The final step will be to test it in people.
Geibel is eager to advance to this point, and to give people
who are suffering from life-altering health complications
hope for a viable replacement that can restore functionality
to damaged tissue. /yale medicine magazine
Adrian Bonenberger is editor of Yale Medicine Magazine.
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Exploring the
frontiers of immunity
and healing
by katherine l. kraines | otto steininger illustration
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Exploring the frontiers of immunity and healing

Researchers at Yale
are aware of how
wounds know to heal.
Now they want to
know why.

During a 1989 lecture at the Cold Spring Harbor
Symposium on Quantitative Biology, Yale School of
Medicine professor Charles Janeway, MD, hypothesized the existence of an innate immune system and
special receptors on immune cells (currently known
as toll-like receptors) that trigger the body’s response
to infection. Janeway’s research later confirmed his
insights, providing the foundation of future endeavors exploring the intricacies of the human immune
response. New discoveries continue to reveal an exquisitely tuned immune system in which inflammatory
responses and healing are initiated and regulated by
known and unknown mechanisms.
Carla Rothlin, PhD, the Dorys McConnell Duberg
Professor of Immunobiology and professor of pharmacology, and co-leader, cancer immunology, Yale
Cancer Center; and Sourav Ghosh, PhD, associate
professor of neurology and pharmacology, run Yale’s
Rothlin Ghosh Laboratory. “We focus on mechanisms
that set or limit the magnitude of the immune
response,” said Rothlin, “as well as mechanisms that
signal the shift from a pathogen-defense mode following successful immune defense to resolution and
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wound repair.” The team is also studying the different types of inflammation that occur as part of
the immune response and are examining immune
mechanisms that play a role in the healing process.
Rothlin and Ghosh’s partnership began as postdoctoral fellows at the Salk Institute for Biological Studies,
where they started to understand the role of three cell
receptors: Tyro3, Axl, and MerTk, known as the TAM
receptor tyrosine kinases. While found on other cells,
these receptors are primarily expressed on the plasma
membrane of innate immune cells known as macrophages and dendritic cells. Continuing their investigations at Yale, Rothlin and Ghosh found that the TAMs
are also essential to the healing process.
“Our lab discovered that the TAM receptors serve
as innate immune checkpoints in regulating the
magnitude and duration of the immune response by
working to negatively regulate the response. In other
words, they operate as brakes on the inflammatory
response,” Rothlin said. “The goal is to mount an adequate response to fight the bacteria, virus, or parasite
and not kill you. This process must also regulate the
immune response to bring the body back to baseline.

The TAM receptors play a pivotal role in the homeostatic regulation of the immune system.”
The immune or inflammatory response is a finely
tuned classical feedback loop that begins with tolllike receptors, located with the TAMs on macrophages,
reading the presence of a pathogen and activating
inflammation. The TAM receptors are downstream of
this positive signal and are activated to tell the toll-like
receptors to slow down the inflammatory response
so it is not overdone. Once the pathogen is gone, the
TAMs identify a type of dead cell associated with the
transition to resolution of inflammation and induction of tissue repair, and start the healing process by
triggering macrophages to eat the cells and produce
growth factors to make new ones. “What is beautiful
is the immune system can kill invading pathogens and
repair the damage after inflammation, and we have
found that that is contributed to, in part, by the TAM
receptors,” said Rothlin.
Together the TAMs serve as negative regulators of
the immune response, but each receptor has selectivity of function related to the kind of inflammation that
occurs. Some TAM receptors function better as brakes
on a bacterial or viral infection, and others are more
effective with an allergic response. “Key to understanding the role of TAMs is knowing that there are
different types of inflammation,” Rothlin said. “Being
infected with a virus is different from mounting an
allergic response. We discovered that the “T” in TAM—
Tyro3—is a negative regulator of type 2 inflammation,
which is an allergic response.”
The immune system has an amazing ability to
recognize invading microorganisms, react, and eliminate them, and to coordinate healing. Yet healing
is not only dictated by the macrophages, but also by
the location of the damage. “Different tissues have
different capacities to recover,” said Rothlin. “Our
skin and mucosa are in touch with the environment
and heal better because they are more likely to be
damaged. However, the brain and heart are not
that good at healing. You cannot easily make more
neurons or cardiomyocytes.”
Much is still unknown about the immune mechanisms in autoimmune diseases or cancer. Current
drugs to treat autoimmune diseases suppress the

response, but Rothlin noted that the resulting inflammatory damage still requires healing. “Autoimmunity
is complex and is a result of many, many changes
happening together,” she said. “Targeting the TAM
receptors might help healing by allowing us to put
the brakes on chronic inflammation or to release the
brakes to allow the immune system to persist in a
sustained way against something like cancer.”
Moving forward, understanding the transition
from inflammation to tissue repair is going to be very
important. “We have medications that reduce inflammation, but we have nothing to induce healing,” said
Rothlin. “Studying what these receptors can do may
allow us to develop therapeutics that not only limit
inflammation but also promote tissue repair.” /yale
medicine magazine
Katherine L. Kraines is a frequent contributor to Yale Medicine
Magazine.
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capsule

to glimpse the actual
inflammatory process
thanks to the invention of
the microscope.
The Dutch medical professor Herman Boerhaave

		 The intricate history of
a long-familiar companion
			 of tissue injury
			 Inflammation has captured the
		 interest of generations of distinguished
				 clinicians and researchers.
		

By Jenny Blair, MD ’04 and Rebecca Frey, PhD ’99

(1668–1738) peered at
blood vessels in inflamed
tissue, decided they were
too small to conduct blood,
and proposed that calor
arises from the blood’s
generating friction. His
German-born student
Hieronymus David Gaubius
(1705–1780), whom history will also remember as
the discoverer of menthol,
correctly linked inflammation to coagulation.
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»

		 Around the
world in six years
growing up in la rioja, spain—wine country—Judit
Jimenez Sainz, PhD, was surrounded by people involved
with the production of its famous red. Her grandfather
made wine; both of her uncles own vineyards; and as a
little girl, she picked grapes from the vines.
In high school, though, Jimenez
Sainz decided on a path a long
way from viticulture. Her teachers, glimpsing a talent for science and research, advised her
to explore those fields. And
although her first thought as a
young woman was that science
is for men, she trusted her mentors. When it came time for college, they encouraged her
to find the best institution to
feed her curiosity.
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“I’m very grateful to my
teachers for helping me challenge myself,” said Jimenez
Sainz. “They were instrumental to pushing me to seek out
opportunities in research.”
Jimenez Sainz decided to study
at the University of Valencia,

where she took her PhD. She
also spent a year in the United
Kingdom at University College
London, broadening her
research capabilities and her
professional network. But her
journey was just beginning.
“I am a biochemist and
molecular biologist who focuses
on breast and ovarian cancer
in women, and ways to identify, prevent, and (I hope) cure
it,” said Jimenez Sainz. “I ended
up in New Haven because
that’s where I had the best
feeling about my PI [principal
investigator].”
Jimenez Sainz had heard of
Yale—“Of course, everybody
knows about the Ivy League in
Europe”—but hadn’t realized it
is in New Haven, Conn.—a place
unfamiliar to her. Originally set
on working in a big city “like
Boston or New York,” Jimenez
Sainz was ultimately drawn
to the research possibilities at
Yale, the academic culture, and
sense of optimism she felt about
her lab. Now, she is an associate research scientist with the
Jensen Lab in the Department of
Therapeutic Radiology.
It didn’t take long for Jimenez
Sainz to adapt to New Haven.
And while she was adjusting
to the United States, she dove
headfirst into her research
and also into the community, becoming involved with
the E-visibility program (of
which she is now director) and
Españoles Científicos en USA
(ECUSA: Spanish Scientists in
the United States). She is also a

Judit Jimenez Sainz’s
research brought her
from her native Spain
to England, and now,
to the United States.
Her advocacy for
gender equality in
science and medicine
will bring her to
Antarctica this fall.

A N T H O N Y D E C A R LO P H OTO

strong advocate of women in science, which is how she came to
participate in a program called
Homeward Bound that will send
her to spend three weeks in
Antarctica later this year.
“Homeward Bound is an international leadership, scientific,
and visibility initiative that aims
to bring 1,000 STEMM [science,
technology, engineering, math,

and medicine] women across the
globe in 10 years,” said Jimenez
Sainz. Part of the cohort HB5,
Jimenez Sainz discusses the program and fundraising for it on
her webpage.
Why leadership? “Just like I
had to learn how to do experiments properly, I need to learn
more about the craft of leadership,” she said. “I hate to say it,
but growing up, it didn’t even
occur to me that I could be a
scientist, let alone a department
head or a dean. I thought, to be
honest, that these were jobs for

men. I have a lot of catching up
to do with leadership training.”
Hence the culminating
three-week trip to Antarctica.
“Until 1969, women were forbidden from Antarctica. Not
because of any laws—there is
no government in Antarctica.
Just because with a very small
number of exceptions, they
weren’t brought on scientific
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After graduating
from Yale School of
Medicine, Howard Koh
served as Commissioner of Public Health for
the Commonwealth
of Massachusetts and
the Assistant Secretary for the United
States Department of
Health and Human
Services under President Barack Obama.
He shares some of his
insights into how to
achieve lasting success
in life.
For more on lasting
success, visit ymm.yale.
edu/success

expeditions or military operations. The prohibition was, from
a certain perspective, selfimposed: women thought that it
would be impossible for them to
go to Antarctica, that they had
nothing to contribute to such an
expedition. Homeward Bound
helps foster leadership, and selfstarting is part of that,” said
Jimenez Sainz. “I’m looking forward to what the future holds.”
—Adrian Bonenberger

»

Paying it back:
Kristina Brown’s quest

Chronic disability casts a
shadow over the lives of people
who live with it. One can never
be sure when the condition or
illness will flare up or be permanently exacerbated. Even when
times are good, it’s difficult to
focus fully on long-term projects
like career or education, knowing that a setback could be just
around the corner.
Kristina Brown’s mother’s
multiple sclerosis was under
control for much of Brown’s
childhood, and her family was
financially healthy. That changed
when Brown was a teenager
and her mother’s disease worsened to a debilitating level. Her
mother’s need for home care
required Brown to devote significant time each day when she
was still just in high school. Her
parents divorced when Brown
was in college, further reducing
resources available for care. Only
Brown and one of her sisters
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acting as caregivers kept their
mother alive.
So it was that when Brown
was accepted to Yale School
of Medicine (YSM), normally
among the happiest days in a
young student’s life, she was
faced instead with a terrible
choice: continue caring for her
mother at home, foregoing a
career in medicine, or pursue
her dream and accept major
financial risk and indebtedness
by taking out student loans
to not only pay for her education but also for the care of
her mother.
Luckily for Brown, for YSM,
and for the United States, she
took the latter path. Now a
fourth-year student at YSM, she
has a lot to say on the subject of
equitable treatment of individuals with disabilities as well as
fair compensation for caregivers. “We have a health system
that is full of gaps, where entire
groups of people are routinely
overlooked,” said Brown. “And
we have an economic system
where caregivers go into debt
and make unthinkable sacrifices taking care of loved ones.
It doesn’t have to be this way.”
The gap to which she refers,
and which is referenced in an
op-ed she published in the
Washington Post, has to do with
health insurance coverage. Her
mother made too much money
to qualify for Medicaid, a health
care system that covers the
poor, but her private insurance
did not cover home health care
for such daily needs as bathing

and personal hygiene. And in
any case, private insurance did
not leave Brown’s mother with
enough money to pay for home
care along with a mortgage and
all other expenses. Medicare,
the health system that covers
elderly patients, kicks in only
when one reaches 65. What is a
middle-aged, middle-class disabled person to do?
Brown wrote about the
dilemma. Titled “My family
faces an impossible choice: caring for our mom, or building our
future,” the article took months
of drafting and energy, as well
as some assistance from a writing mentor, Anna Reisman, MD.
When the Washington Post
published the article, it went
viral, and Brown received an
invitation to testify in front of
Congress a week later. She did so
at a hearing in honor of National
Alzheimer’s Disease Awareness
Month and National Family
Caregivers Month. “It was a
great honor to get to speak in
front of Congress,” she said.
Hopeful about the potential for future reforms, Brown
said that extended disability
is something that everyone
should care about. “If you’re in
the middle class, it can happen
to you,” she said. “Imagine your
son or daughter donating hours
of their lives to your care out
of financial necessity. That’s the
reality many Americans live
with today.”
The article has had two outcomes that give Brown great
hope: first, responses by people

A N T H O N Y D E C A R LO P H OTO

in her position who have said
the op-ed inspired them and
made them realize they aren’t
alone; and second, opportunities to cover expenses while
she’s still in New Haven and
unable to give her mother the
necessary assistance.
One such source of assistance
is a GoFundMe page that Brown
set up with the goal of raising
$80,000 for home care for her
mother. As of this writing, she
has raised $14,339 of the total
needed—a not-inconsiderable
sum, though short of her goal.
“I thought about leaving medical school before the piece came
out, to return to caregiving for
my mother,” said Brown. “I had
explored and applied for every
option for financial assistance,
and without any forthcoming,
I felt trapped and desperate. The
community has responded so
well, it’s amazing.”
Brown’s next stop will
be residency at UCLA, in
Medicine-Pediatrics. She hopes
this will help her to grow as an
advocate for individuals who
through no fault of their own
lack voices; those with disabilities; and those systemically disenfranchised by dysfunctional
political institutions.
—Adrian Bonenberger

Kristina Brown published
an op-ed with the Washington Post in 2019 about
the difficulty of being a
caregiver for her mother,
who suffers from MS. The
piece resonated deeply
with other Americans,
and was widely read and
shared, landing Brown
an opportunity to testify
in front of Congress the
following week. Now she’s
carrying that advocacy
work forward with her.

Winter 2020 45

question and answer

helped care for a patient
with systemic lupus
erythematosus (SLE), an
autoimmune disease that
has no cure as of 2020.
Craft decided then that
he wanted to understand
immunology through
lupus. “It was a very
mysterious disease at the
time,” Craft said. “It still
is, but we know a lot more
about how it works.”
Since he arrived at
Yale in 1980, Craft’s

			 The machinery
		 of immune systems
F RO M A YO U N G AG E ,

immunology research
has focused on how lupus
develops, along with
different aspects of the
immune system’s response

Joseph Craft, MD, FW ’85, the Paul B.

Beeson Professor of Medicine (Rheumatology) and professor of
immunobiology, adopted a problem-solving approach to chores
on his childhood 300-acre farm in rural North Carolina. If a
piece of farm machinery shuddered to a stop in the middle of a
cornfield, Craft inspected every piston, rod, and washer in the

vaccines. He directs the
Investigative Medicine
Program for physicians
who earn a PhD while gaining experience in the lab
or in-patient research. In
2004, he won Yale’s prestigious Charles W. Bohmfalk
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as well as follicular B helper
T cells (TFH), which his
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		Permission
to feel
By Cathy Shufro
Our vocabulary for emo-

“You don’t want other people

tion is impoverished. We’re

to think they need to take

stressed or we’re good; we’re

care of you,” said Brackett.

bummed or we’re okay. The

In his new book,

said. Recently, he’s begun

of our storytelling ability,

using meetings to take walks.

perspective-taking skills,

Groups of colleagues will
also fare better if they share

together the concatenation

meagerness of this lexicon

Permission to Feel: Unlocking

feelings. For instance, at a

of feelings and events that

tells us something about

the Power of Emotions to

casino where Brackett served

led to the current situation.

ourselves, according to

Help Our Kids, Ourselves,

as a consultant, workers

It begins with being an emotion scientist, not a judge.”

psychologist Marc Brackett,

and Our Society Thrive,

quit frequently because they

PhD: It shows how hazily we

Brackett helps readers find an

were worn down by being

perceive our feelings.

emotional equilibrium, or a

around gamblers who were

emotions requires listening,

“best self.” That self is at once

drunk or angry about losing

so does finding the best way

age may be particularly

collected and compassion-

money. Scheduling time for

to help someone in distress.

undiscerning. It’s an occu-

ate, Brackett writes. Using

the workers to talk over the

Brackett suggests asking such

And physicians on aver-

Just as understanding

open-ended questions as,

pational hazard: As doctors

stories of deprivation and

emotional toll of their work

rush from patient to patient,

distress from his own child-

reduced turnover. Brackett

they can’t take time to reflect

hood, Brackett provides a

suggests that group medi-

on feelings. And when they

method for realizing that best

cal practices schedule time

witness the suffering caused

self: recognizing and regulat-

for meetings whose sole aim

course at Yale College called

by illness and death, one way

ing emotions, and learning to

is to “to provide time and

Emotional Intelligence that

they cope is to drive emo-

express feelings judiciously

space to just process.”

tions underground.

in accord with the situation.

Checking in with one’s

“What do you need right now?
How can I support you?”
Brackett teaches a

draws hundreds of students.
Sometimes a student will tell

Acknowledging feelings, he

emotions also prevents a

him, “I didn’t need emotional

work, said Brackett, direc-

said, “prevents emotions from

reaction to one situation from

intelligence to get into Yale, so

tor of the Yale Center for

having undue influence over

coloring the next interaction.

why is it so important?” And

Emotional Intelligence and

our actions.”

Except suppression doesn’t

professor in the Child Study

The best self shows sym-

Center. When doctors habitu-

pathy not only for others

“If you name it, you can tame

doctors have said, “I’ve got-

it,” Brackett said. “Once you

ten here without those skills.”

attribute that emotion to its

Brackett’s answer: “ ‘What

ally suppress their feelings,

but also compassion for the

source, it no longer will have

about the quality of your rela-

they burn out, even get sick.

self. For instance, when a

a subconscious influence on

tionships? What about your

And patients view emotionally

patient dies, a doctor might

how you interact in that sec-

physical health? What about

ond setting.”

your mental health?’ It’s a

blank doctors as heartless. On

tell himself or herself, “You

the other hand, patients don’t

really did everything pos-

benefit from seeing their phy-

sible to support this person.”

tions of another person, he

sicians sobbing uncontrollably.

Brackett also recommends

writes, “requires the use

Understanding the emo-

{ Send notices of new books to

narrow definition of success.”
Real flourishing, he argues, for
the individual and for society,

giving priority to self-care.

will arise when we give our-

“My workouts and yoga ses-

selves—and others—permis-

sions are in my calendar,” he
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and pattern-seeking to piece

sion to feel.
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end note

Hail and Farewell
ON ON E OF T HE COL DER E V EN INGS

of an unusually warm winter, dozens of faculty, faculty

emeriti, and department chairs gathered in Yale School of Medicine (YSM)’s Medical Historical
Library to shake hands with the new dean and raise their glasses to the former dean.
The affair was comfortable and familiar, with Nancy J. Brown, MD, the Jean and David W.
Wallace Dean of Medicine and C.N.H. Long Professor of Internal Medicine, mingling and chatting
with her new colleagues. She said she begins her journey as dean with YSM in “an incredible place,
due largely to the leadership of Bob Alpern.” Robert J. Alpern, MD, Ensign Professor of Medicine
and professor of cellular and molecular physiology, partook in the festivities, basking in the glow of
15 years’ efforts successfully handed over to a capable and competent successor. With that, one era
was over, and another began.
—Adrian Bonenberger
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